# OnCo record nct06968585 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06968585/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06968585", "NCT06968585" ;
  schema:name "A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy"@en ;
  schema:description "A phase 3 trial testing A166 in HER2-positive breast cancer, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06968585/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06968585> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2023-07-18" ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/> ;
  onco:drugs <https://onco.cc/drugs/a166/> ;
  onco:companies <https://onco.cc/companies/kelun-biotech/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct06968585-j-clin-oncol-2026/> .